Meta-analysis of brain and blood transcriptional signatures of neuroimmune dysregulation in Schizophrenia: convergent evidence for excessive complement system activity and CX3CL1-CX3CR1 axis disruption.

Brain Behav ImmunJun 11, 2026 (epub)
Clinical ResearchPsychiatry

Mohamed-ElMehdi Boughanmi, Louis-Ferdinand Lespine, Marion Leboyer et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined transcriptional changes in neuro-immune regulators (NIREGs) in 532 individuals with schizophrenia compared to 623 healthy controls. The study found that schizophrenia is associated with C4 overexpression and altered expression of NIREGs, including underexpression of CX3CL1 and CD46 in brain tissue, and underexpression of CX3CR1 in peripheral blood, indicating immune dysregulation.

Key findings

  • Schizophrenia was linked to C4 overexpression and underexpression of CD46 and CX3CL1 in brain tissue.
  • In peripheral blood, CD46, CD55, and CD59 were overexpressed, while CX3CR1 was underexpressed.
  • Disruption of the CX3CL1-CX3CR1 axis was observed in both brain and blood tissues.
  • Sex-specific transcriptional differences were noted for CD200 and CX3CR1.

Why it matters

Understanding the transcriptional alterations in neuro-immune regulators may provide insights into the pathophysiology of schizophrenia and highlight potential biomarkers for diagnosis or monitoring.

Source

PubMed · PMID 42276261

Published in Brain Behav Immun. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.